Abstract | BACKGROUND: METHODS: RESULTS: Serum CRP concentrations were 23% lower after glucosamine and chondroitin compared to placebo (P = 0.048). There were no significant differences in other biomarkers. In the proteomics analyses, several pathways were significantly different between the interventions after Bonferroni correction, the most significant being a reduction in the " cytokine activity" pathway (P = 2.6 x 10-16), after glucosamine and chondroitin compared to placebo. CONCLUSION: TRIAL REGISTRATION: ClinicalTrials.gov NCT01682694.
|
Authors | Sandi L Navarro, Emily White, Elizabeth D Kantor, Yuzheng Zhang, Junghyun Rho, Xiaoling Song, Ginger L Milne, Paul D Lampe, Johanna W Lampe |
Journal | PloS one
(PLoS One)
Vol. 10
Issue 2
Pg. e0117534
( 2015)
ISSN: 1932-6203 [Electronic] United States |
PMID | 25719429
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Anti-Inflammatory Agents
- Biomarkers
- Blood Proteins
- Chondroitin
- Glucosamine
|
Topics |
- Adult
- Anti-Inflammatory Agents
(administration & dosage, adverse effects, pharmacology)
- Biomarkers
(blood)
- Blood Proteins
(metabolism)
- Chondroitin
(administration & dosage, adverse effects, pharmacology)
- Dietary Supplements
(adverse effects)
- Female
- Glucosamine
(administration & dosage, adverse effects, pharmacology)
- Healthy Volunteers
- Humans
- Male
- Middle Aged
- Overweight
(blood)
- Oxidative Stress
(drug effects)
|